Platelet inhibition: New agents, new strategies, new trials

Fibrinolysis and Proteolysis

Volumn 12, Issue SUPPL. 2, 1998, Pages 13-23

  Gulba, D C ^a,c   Huber, K ^b   Moll, S ^a   Dietz, R ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; L 7000482; LAMIFIBAN; LEFRADAFIBAN; ORBOFIBAN; SC 54884; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG POTENCY; ENDOTHELIUM CELL; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR BLOCKING; RISK BENEFIT ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; UNSTABLE ANGINA PECTORIS;

EID: 0031735984     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80303-2     Document Type: Conference Paper

References (87)

1. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myoardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-373.
2. Davies MJ, Woolf N, Rowles PM, Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J 1988; 60: 459-464.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92(3): 657-671.
4. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989; 63: 114E-120E.
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-250.
6. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 92: 310-318.
7. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559.
8. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995; 130: 877-892.
9. Théroux P, Fuster V. Acute coronary syndromes. Unstable angina and non-Q-wave myocardial infarction. Circulation 1998; 97: 1195-1206.
10. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111.
11. The RISC study group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstabe coronary disease. Lancet 1990; 336: 827-830.
12. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative Study. N Engl J Med 1983; 309: 396-403.
13. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313: 1369-1375.
14. ISIS-2 (Second International Study of Infarct Survival) Collaboraive Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; II: 349-360.
15. Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In. Colman RW, Hirsh J, Marder VJ, Salzmann EW (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, J.B. Lippincott, 1994: 3-18.
16. Born GVR. Platelets in atherogenesis and thrombogenesis. In: Kakkar W (ed). Atheroma and Thrombosis. London, Pitman, 1985: 143-152.
17. Hirsh J, Salzman EW, Marder VJ, Colman RW. Overview of the thrombotic processes and its therapy. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, J.B. Lippincott, 1994: 1151-1163.
18. Coller BS. Blood elements at surfaces: platelets. Ann N Y Acad Sci 1987; 516: 362-379.
19. Smyth SS, Joneckis CC, Parise LV. Regulation of vascular integrins. Blood 1993; 81: 2827-2843.
20. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of integrins. Med Res Rev 1994; 14: 195-228.
21. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907-914.
22. Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell 1991; 65: 359-362.
23. Detwiler TC, Charo IP, Feinman RD. Evidence that calcium regulates platelet function. Thromb Haemost 1978; 40: 207-211.
24. Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE (eds). The Heart and Cardiovascular System. New York, Raven Press, 1992: 219-273.
25. Gachet C, Stierlé A, Cazenave JP. The thienopyridine PCR 4099 selectively inhibits ADP-innduced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb/IIIa complex in rat and in man. Biochem Pharmacol 1990; 40: 229-238.
26. Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 4: 252-261.
27. Andrieux A, Rabiet MJ, Chapel A, Concord E, Marguerie GA. A highly conserved sequence of the Arg-Gly-Asp domain of integrin beta 3 subunit is sensitive to stimulation. J Biol Chem 1991; 266: 14202-14207.
28. Nurden AT, Caen JP. Abnormal platelet glycoprotein patterns in three cases of Glanzmann's thrombasthenia. Br J Haematol 1974; 28: 253-260.
29. Phillips DR, Agin PP. Platelet membrane defects in Glanzmann's thrombasthenia: evidence for decreased amounts of two major glycoproteins. J Clin Invest 1977; 60: 1393-1401.
30. Rao AK, Holmsen H. Congenital disorders of platelet function. Semin Hematol 1986; 23: 102-118.
31. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Curr Opin Cardiol 1995; 10: 420-426.
32. Cook NS, Kottirsch G, Zerwes H-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs of the Future 1994; 19: 135-159.
33. Jennings LK, Phillips DR. Purification of glycoprotein IIb and IIIa from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb/IIIa complex. J Biol Chem 1982; 257: 10458-10466.
34. D'Souza SE, Ginsberg MH, Burke TA, Plow EF. Localization of an arg-gly-asp recognition site within an integrin adhesion receptor. Science 1988; 242: 91-93.
35. Plow EF, D'Souza SE, Ginsberg MH. Ligand binding to GPIIb/IIIa: a status report. Semin Thromb Hemostas 1992; 18: 324-332.
36. Charo IF, Nannizzi L, Phillips DR, Hsu MA, Scarborough RM. Inhibition of fibrinogen binding GP IIb/IIIa by a GP IIIa peptide. J Biol Chem 1991; 266: 1415-1421.
37. D'Souza SE, Ginsberg MH, Burke TA, Plow EF. The ligand binding site of the platelet integrin receptor GP IIb-IIIa is proximal to the second calcium binding domain of its alpha subunit. J Biol Chem 1990; 265: 3440-3446.
38. Taylor DB, Gartner TK. A peptide corresponding to GP IIb alpha 300-312, a presumtive fibrinogen gamma chain binding site on the platelet GP IIb/IIIa inhibits the adhaesion of platelets to at least four adhesive ligands. J Biol Chem 1992; 267: 11729-11733.
39. Gartner TK, Taylor DB. The amino acid sequence Gly-Ala-Pro-Leu appears to be a fibrinogen binding site in the platelet integrin glycoprotein lib. Thromb Res 1990; 60: 291-309.
40. Du X, Plow EF, Frelinger AL, O'Toole TE, Loftus JC, Ginsberg MH. Ligands 'activate' integrin alpha lib beta 3 (platelet GP IIB/IIIa). Cell 1991; 65: 409-416.
41. Marguerie GA, Edington TS, Plow ER Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980; 255: 154-161.
42. Müller B, Zweres H-G, Tangemann K, Peter J, Engel J. Two-step binding mechanism of fibrinogen to alpha IIb beta3 integrin reconstituted into planar lipid bilayers. J Biol Chem 1993; 268: 6800-6808.
43. Scarborough RM, Rose JW, Hsu HM, et al. Barbourin: a GP IIb/IIIa specific integrin antagonist from the venom Sistrurus M. barbouri. J Biol Chem 1991; 266: 9359-9362.
44. Schrör K. Antiplatelet drugs. Drugs 1995; 50: 7-28.
45. D'Souza SE, Ginsberg MH, Matsueda GR, Plow EF. A discrete sequence in a platelet integrin is involved in ligand recognition. Nature 1991; 350: 66-68.
46. Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci 1991; 11: 444-451.
47. Coller BS. A new murine monoclonal antibody reports an activation dependent change in the conformation and or microenvironment of the glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101-108.
48. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor. Circulation 1989; 80: 1766-1774.
49. Faulds D, Sorkin EM. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischemic heart disease. Drugs 1994; 48: 583-598.
50. Nichols AJ, Ruffolo RR, Huffman WF, Poste G, Samanen J. Development of GPIIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 1992; 13: 413-417
51. Coller BS. GP IIb/IIIa-antagoniss: pathophysiology and therapeutic insights from studies on c7E3-Fab. Thromb Haemostas 1997; 78: 730-735.
52. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-884.
53. Crenshaw BS, Harrington RA, Tcheng JE. Novel antiplatet agents: the glycoprotein IIb/IIIa inhibitors. Exp Opin Invest Drugs 1995; 4: 1033-1044.
54. Gold HK, Gimple LW, Yasuda T, Coller BS. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-659.
55. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-1764.
56. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab after thrombolytic therapy. JACC 1993; 22: 381-389.
57. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
58. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-1435.
59. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of Integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996; 94: 2083-2089.
60. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.
61. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of Tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996; 27: 536-542.
62. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
63. Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIa receptor. In: Sasahara AA, Loscalzo J (eds). New Therapeutic Agents in Thrombosis and Thrombolysis. New York, Marcel Decker, 1997: 355-365.
64. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists - Peptide antagonists with high specifity for glycoprotein IIb-IIIa. J Biol Chem 1993; 268: 1066-1073.
65. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term Abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680-1688.
66. 3 blockade with percutaneous coronary intervention. J Am Med Assoc 1997; 278: 479-484.
67. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222-1227.
68. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
69. The PARAGON Investigators. International randomized controlled trial of Lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386-2395.
70. Moliterno DJ, Harrington RA, Newby KL, et al. Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON Study 1-year follow-up. J Am Coll Cardiol 1998; 31 suppl. A:A-208(Abstract).
71. Brener SJ, Barr LA, Cohen ED, et al. Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT Trial. J Am Coll Cardiol 1998; 31 suppl A:A-54 (Abstract).
72. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled dose-ranging trial. Circulation 1997; 95: 846-854.
73. Antmann EM, Giugliano RP, McCabe CH, et al. Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results of TIMI 14 trial. J Am Coll Cardiol 1998; 31 suppl A:A-191 (Abstract).
74. Gulba DC, Tanswell P, Dechend R, et al. Sixty minutes alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1611-1617.
75. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activator. Circulation 1997; 95: 1755-1759.
76. Aguirre F, Ferguson JJ, Califf RM, for the EPIC Investigators. Clinical predictors of bleeding complications in high risk angioplasty: results from the EPIC Study Group. Circulation 1993; 88 suppl I:I-252 (Abstract).
77. Giugliano RP, Hyatt RR Ir. Thrombocytopenia with GP IIb/IIIa inhibitors: a meta-analysis. J Am Coll Cardiol 1998; 31 suppl. A:A-185 (Abstract).
78. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114.
79. Frelinger AL, Du XP, Plow EF, Ginsberg MH. Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb/beta 3 (glycoprotein IIb/IIIa) alter receptor affinity, specificity, and function. J Biol Chem 1991; 266: 17106-17111.
80. Frelinger AL, Lam SC-T, Plow EF, Smith MA, Loftus JC, Ginsberg MH. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem 1988; 263: 12397-12402.
81. Tcheng JE, Kereiakes DJ, George BS, et al. Safety of readministration of abciximab; interim results of the ReoPro readministration registry (R3). J Am Coll Cardiol 1998; 31 suppl. A:A-55 (Abstract).
82. Cook J, Glass J, Sitko G, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. Circulation 1997; 96: 949-58.
83. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral Xemilofiban in 170 patients after coronary stent deployment. Circulation 1997; 96: 1117-1121.
84. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, Sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 trial. Circulation 1998; 97: 340-349.
85. The platelet receptor inhibition in ishemic syndrome management. (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-1505.
86. The platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and syptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl J Med 1998; 338: 1488-1497.
87. The Pursuit trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-443.